diabetes mellitus type 2. Non-insulin dependent diabetes mellitus
Conditions
Interventions
Placebo
30 mg zinc (zinc gluconate) daily
one plasebo tablet daily
Intervention 1: 30 mg zinc (zinc gluconate) daily. Intervention 2: one plasebo tablet daily.
Treatment - Drugs
Sponsors
Endocrinology & Metabolism Research Center
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 30 to 50 years, presence of type 2 diabetes at least for one year, willingness to participate in the study and sign the informed consent, BMI=25-30, HbA1C=8.5, Blood pressure =135/85 mmHg. Exclusion criteria: severe kidney, heart, liver, GI, pulmonary and infectious diseases, thyroid dysfunction, active cancer, previous myocardial infarction, recent surgery, Insulin therapy, changing in dose of medications such as oral anti-diabetic, anti-lipidemic and anti-hypertensive drugs 3 month before and during the study, consumption of vitamin-mineral supplements 6 month before and during the study, consumption of non-steroidal anti inflammatory drugs, glucocorticoids, hormonal drugs, antidepressants, psychotropic medications, antibiotics, dioretics, three months prior to study, Following weight-reducing diet 3 months before and during the study, smoking, pregnancy, breast feeding, postmenopausal women.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma adiponectin. Timepoint: Baseline and after 12 weeks. Method of measurement: ELISA assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: Baseline and after 12 weeks. Method of measurement: Glucose oxidase, Enzymatic colorimetric.;Fasting insulin serum. Timepoint: Baseline and after 12 weeks. Method of measurement: ELISA assay.;HbA1C (Glycosilated hemoglobin). Timepoint: Baseline and after 12 weeks. Method of measurement: Ion exchange method.;Insulin resistance. Timepoint: Baseline and after 12 weeks. Method of measurement: HOMA-IR calculation.;Serum triglyceride. Timepoint: Baseline and after 12 weeks. Method of measurement: Glycerol phosphate oxidase, Enzymatic colorimetric.;Total cholestrol. Timepoint: Baseline and after 12 weeks. Method of measurement: Enzymatic photometric.;HDL-cholestrol. Timepoint: Baseline and after 12 weeks. Method of measurement: Enzymatic.;LDL-cholestrol. Timepoint: Baseline and after 12 weeks. Method of measurement: Enzymatic.;HsC-Reactive Protein. Timepoint: Baseline and after 12 weeks. Method of measurement: ELISA assay.;Serum zinc. Timepoint: Baseline and after 12 weeks. Method of measurement: atomic absorption spectrophotometery. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSomayyeh Asghari
Nutrition and Biochemistry Department, School of Health, Tehran University of Medical Sciences
Outcome results
None listed